Summary & Overview
CPT 0438U: EffectiveRX™ Pharmacogenomic Panel, 33 Genes
CPT code 0438U represents a Proprietary Laboratory Analyses (PLA) test — the EffectiveRX™ Comprehensive Panel from RCA Laboratory Services LLC, d/b/a GENETWORx — that performs variant analysis of 33 genes and CYP2D6 duplication/deletion testing from a buccal swab to produce patient-specific drug–response phenotypes and gene–drug interaction information. Such pharmacogenomic panels are increasingly used to inform medication selection and dosing and can influence prescribing practices at a national level.
Key payers covered in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of coverage considerations and common payer practices, benchmark indicators for lab-based molecular diagnostics, and clinical context on how pharmacogenomic test results are applied to personalized medication planning. The publication also summarizes coding details, typical sites of service, and available data elements. Data not available in the input include associated taxonomies, specific ICD-10 diagnoses, related codes, and detailed payer-specific reimbursement rates.
Billing Code Overview
CPT code 0438U is a Proprietary Laboratory Analyses (PLA) code that describes the EffectiveRX™ Comprehensive Panel produced by RCA Laboratory Services LLC, d/b/a GENETWORx. The test analyzes genetic variants across 33 genes and includes duplication/deletion evaluation for the CYP2D6 gene using a buccal (cheek) swab specimen. Results are used to generate a personalized treatment plan that reports patient drug–response phenotypes and gene–drug interactions based on established clinical drug data.
Service type: Genetic pharmacogenomic testing / molecular diagnostic assay
Typical site of service: Outpatient laboratory or clinician office where buccal swab specimens are collected, with laboratory processing performed by the proprietary lab.
Clinical & Coding Specifications
Clinical Context
A 45-year-old patient with a history of multiple medication trials for major depressive disorder and persistent treatment-emergent adverse effects is referred by a primary care physician to a psychiatric clinic for pharmacogenomic testing. The clinician orders the EffectiveRX™ Comprehensive Panel (0438U) from GENETWORx to assess single nucleotide variants across 33 pharmacogenes and CYP2D6 copy-number variation using a buccal swab. The patient provides informed consent, completes a buccal swab collection at the clinic, and the specimen is forwarded to the laboratory. The lab performs variant analysis and duplication/deletion testing for CYP2D6, interprets results relative to established drug–gene interaction databases, and returns a report that includes patient drug–response phenotypes and a personalized medication guidance summary. The clinician reviews the report with the patient to inform medication selection and dosing adjustments, documents the test result in the electronic medical record, and communicates changes to the prescribing providers and pharmacy as needed.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Procedure code without modifier | Rarely used; default when no modifier applies |